Introduction
Metabolic syndrome is a multi-component disorder characterized by hypertriglyceridemia, hyperglycemia, abdominal obesity and hypertension, and is closely linked to type 2 diabetes mellitus (1, 2) . The etiology of metabolic syndrome involves the complex interaction between genetic, metabolic, and environmental factors (3) . Obesity is well recognized as the most important health problem related to the genesis of metabolic syndrome, and the rising incidence of this disease throughout the world has generated interest in the underlying mechanisms involved in these pathologies (4).
Obesity is caused by an imbalance between energy intake and expenditure that may lead to the pathological growth of adipocytes (5) . Adipocytes play a central role in regulating adipose mass and obesity. Increased adipose mass in obesity is not only caused by adipose tissue hypertrophy, but also by adipose tissue hyperplasia, which triggers the transformation of preadipocytes into adipocytes (6, 7) . Thus, adipocyte differentiation and the amount of fat accumulation are associated with development of obesity. On the other hand, dysfunctional lipid metabolism is a key component in the development of metabolic syndrome, a very common condition characterized by dyslipidemia, insulin resistance, abdominal obesity, and hypertension, which are all related to an elevated risk of type 2 diabetes mellitus (8) . The liver is an important organ for maintaining lipid metabolism and homeostasis, since it can store (via lipogenesis) or release (as lipoprotein) lipid fuels. Triglycerides (TG) are involved in the ectopic accumulation of lipid stores in the liver and are associated with a number of diseases, such as metabolic syndrome and type 2 diabetes.
Anti-obesity drugs such as orlistat, sibutramine, and topiramate have been used to treat obesity (9) . However, these drugs have many side effects, including dry mouth, anorexia, insomnia, and gastrointestinal distress (10) . Due to the adverse side effects associated with many anti-obesity drugs, recent drug trials have focused on herbal medicines (11) . Under the guidelines of the US Food and Drug Administration, botanical drugs can be developed faster and more cheaply than conventional single-entity pharmaceuticals. Thus, there are many botanicals that might provide safe, natural, and cost-effective alternatives to synthetic drugs. Recent studies have found that natural bioactive compounds can be used to treat obesity in 3T3-L1 adipocytes and in an obese mouse model.
Kangen-karyu (Guan-Yuan-Ke-Li), a crude drug developed from a traditional Chinese prescription consisting of six herbs (Paeoniae Radix, Cnidii Rhizoma, Carthami Flos, Cyperi Rhizoma, Aucklandiae Radix, and Salviae Miltiorrhizae Radix), has been clinically used as a treatment for cardiovascular diseases, such as angina pectoria and cerebrovascular diseases. Kangen-karyu shows biological activity, such as an anti-aging effect, the inhibition of platelet aggregation, a hypotensive effect, and the recovery of learning and memory impairment induced by senescence (12) (13) (14) (15) . In addition, we have reported that Kangen-karyu showed favorable ameliorative effects on fructose-induced metabolic syndrome, such as hyperglycemia, hyperlipidemia, and hypertension, through the reduction of TG and cholesterol levels with the regulation of hepatic sterol regulatory element-binding protein (SREBP)-1 expression, and also exhibited protective effects against diet-induced hypercholesterolemia in rats (16, 17) . We also reported the benefi cial effect of Kangen-karyu on hyperlipidemia in streptozotocin-induced type 1 diabetic rats (18) . These results suggest that Kangen-karyu can ameliorate metabolic disorders such as dyslipidemia and diabetes mellitus. Therefore, this study was designed to determine whether Kangen-karyu affects the differentiation of 3T3-L1 preadipocytes into adipocytes and the mechanism related to its differentiation. We also investigated the effect of Kangen-karyu on diabetic dyslipidemia. For this, db/db mice were used as an experimental model for diabetic dyslipidemia. The db/ db mice develop diabetes mellitus due to a failure to respond to leptin, resulting from a mutation in their receptor gene expressed in the hypothalamus, although gene expression and leptin secretion are markedly augmented in these mice, resulting in leptin resistance (19) . The db/db mice were also characterized by obesity, sustained hyperglycemia, and hyperlipidemia as a result of destroyed leptin receptors (20) .
Materials and Methods

Materials
Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FCS), penicillin, streptomycin, and phosphate-buffered saline (PBS) were purchased from HyClone Laboratories (Logan, UT, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), insulin, dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), oil red O, 2-mercapthoethanol, protease inhibitor cocktail, and β-actin were purchased from Sigma-Aldrich (St Louis, MO, USA). Primary antibodies against peroxisome proliferator-activated receptor (PPAR)γ, PPARα, and SREBP-1c were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Similarly, secondary antibodies for mouse (peroxidase-conjugated affinipure goat anti-mouse IgG) and rabbit (peroxidase-conjugated affinipure goat anti-rabbit IgG) were purchased from Jackson ImmunoResearch Laboratories (Baltimore, USA). The protein molecular weight marker was obtained from Thermo Scientific (Rockford, IL, USA). The nitrocellulose membrane for Western blotting was purchased from Bio-Rad Laboratories (Richmond, CA, USA). Western blot chemiluminescent substrate was purchased from Imgenex (San Diego, CA, USA). Radioimmunoprecipitation assay buffer was purchased from Biosesang (Seoul, Korea). ECL Western Blotting Detection Reagents were purchased from GE Health Care (Piscataway, NJ, USA). All solvents, chemicals, and reagents were of analytical grade and purchased from Sigma-Aldrich unless otherwise specifi ed.
Preparation of Kangen-karyu extract
The composition of Kangen-karyu used in this study is shown in Table 1 starting materials. The extract was dissolved in 50% aqueous ethanol with sonication, and filtered through a Cosmonice filter (PVDF, 0.45 μm; Nakalai Tesque, Kyoto, Japan). Reverse-phase high-performance liquid chromatography was performed using a Cosmosil 5C 18 -AR II column (250 × 4.6 mm i.d.; Nakalai Tesque) with elution gradients of 4-30% (39 min) and 30-75% (15 min) CH 3 CN in 50 mM H 3 PO 4 at a flow rate of 0.8 mL/min. The UV absorbance from 200 to 400 nm was monitored with a Jasco MD-910 photodiode array detector (Jasco, Tokyo, Japan). All assigned peaks were identifi ed by carrying out co-injection tests with authentic samples and comparing with UV spectral data. The major compounds detected were paeonifl orin, pentagalloyl glucose, rosmarinic acid, lithospermic acid, and lithospermic acid B. A voucher specimen has been deposited in the herbarium of the University of Toyama.
Culture cell experiments
Cell culture and differentiation
3T3-L1 preadipocytes obtained from the American Type
Culture Collection (Manassas, VA, USA) were cultured in DMEM containing 10% FCS, 100 μg/mL streptomycin, 100 U/mL penicillin, 44 mM NaHCO 3 , and 1 mM sodium pyruvate at 37 o C under a 5% CO 2 atmosphere. To induce differentiation, 3T3-L1 preadipocytes were cultured until confl uence was reached (day 0), and the culture medium was replaced with a fresh induction medium containing 5 μg/mL insulin, 0.5 mM IBMX, and 1 μM dexamethasone in DMEM with 10% FCS for 2 days. The medium was then replaced with a differentiation medium containing 5 μg/mL insulin only and DMEM medium containing 10% FCS every 2 days for 8 days until the cells were harvested. To examine the effect of Kangen-karyu on adipogenesis, the extract was dissolved in the differentiation medium, and the medium was immediately processed into a sterile container by membrane fi ltration with a 0.22-μm fi lter (EMD Millipore, MA, USA).
MTT assay
3T3-L1 preadipocytes were seeded at a density of 4 × 10 3 cells/well in a 96-well plate. After 4 h, Kangen-karyu extract at concentrations of 25, 50, 125, and 250 μg/mL was added to each well and incubated for 24 h. MTT solution (2 mg/mL) was added to each 96-well plate and incubated for 4 h, and then the medium containing MTT solution was removed. The formazan crystals in the viable cells were solubilized with dimethyl sulfoxide (150 μL), and absorbance was determined at 540 nm with a Microplate Reader (Immuno Mini NJ-2300; BioTec, Tokyo, Japan).
CGG TGC ACG-3', and the reaction cycle was as mentioned above. The obtained PCR products were analyzed in nucleic acid staining solution (Red Safe, iNtRON, Korea)-stained agarose (1.5%) gel by using VisionWorks TM LS UVP (Analysis Software, Upland, CA, USA).
Animal experiments
Experimental animals and treatment
The 'Guidelines for Animal Experimentation' approved by the University of Toyama were followed in the present study (Registration No.: S-2006 INM-22). Male, 5-wk-old, C57BLKS/J db/db mice and their agematched, non-diabetic m/m littermates were purchased from Japan SLC (Hamamatsu, Japan). They were kept in a plastic-bottomed cage and exposed to a 12-h light/dark cycle. Room temperature (about 25ºC) and humidity (about 60%) were controlled automatically. The mice were allowed free access to laboratory pellet chow (CLEA Japan, Tokyo, Japan, comprising 24.0% protein, 3.5% lipids, and 60.5% carbohydrate) and water was given ad libitum. After adaptation, glucose and TG levels of blood taken from the tail vein were measured, and then db/db mice were divided into three groups. The treatment with Kangen-karyu was initiated after confirming the induction of hyperglycemia and hyperlipidemia in the db/db mice, based on the presence of serum glucose 300 ± 10 mg/dL and serum TG 160 ± 5 mg/dL, respectively. The db/db vehicle group (n = 8) was orally given water, while the other two groups (n = 8 per group) were orally administered Kangen-karyu extract every day for 18 weeks at a dose of 100 mg or 200 mg/kg body weight, respectively. The non-diabetic m/m mice (n = 6) as a normal group were compared with the diabetic groups. When the db/db mice reached 24 weeks old, they showed reduced blood glucose, β-cell necrosis, and diminished hyperinsulinemia (21) . Therefore, we decided on the time-point for the cessation of treatment as 24 weeks old in db/db mice. Food and water intakes were determined every day during the experimental period. After administration for 18 weeks, blood samples were collected by cardiac puncture from anesthetized mice. Serum was separated immediately by centrifugation. Subsequently, each mouse was perfused with ice-cold physiological saline, and then the liver was harvested, snap-frozen in liquid nitrogen, and stored at -80°C until analyses.
Measurement of serum parameters
Glucose, TG, total cholesterol, and non-esterifi ed fatty acids (NEFA) were measured using a commercial kit (Glucose CII-Test, Triglyceride E-Test, Cholesterol E-Test, and NEFA C-Test from Wako Pure Chemical Industries, Osaka, Japan). Leptin and insulin (Morinaga Institute of Biological Science, Yokohama, Japan) levels were measured based on enzyme-linked immunosorbent assays. High-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL) cholesterol distributions were measured using a BioVision kit (BioVision, Mountain View, CA, USA). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined using a commercial reagent: GPT-UV Test Wako (Wako Pure Chemical Industries).
Measurement of hepatic TG content
The liver of each mouse was homogenized and total lipids of the liver homogenates were extracted with a mixture of chloroform and methanol (2:1, v/v) according to the method of Folch et al. (22) . Then, the amount of TG was determined using commercial kits, as described previously.
Preparation of nuclear fraction
To prepare nuclear fractions, hepatic tissues were homogenized with ice-cold lysis buffer containing 5 mM Tris-HCl (pH 7.5), 2 mM MgCl 2 , 15 mM CaCl 2 , and 1.5 M sucrose, and then 0.1 M dithiothreitol (DTT) and protease inhibitor cocktail were added. After centrifugation (10,500 × g for 20 min at 4°C), the pellet was suspended with extraction buffer containing 20 mM 2-[4-(2-hydroxyethyl)-1-piperazyl] ethanesulfonic acid (pH 7.9), 1.5 mM MgCl 2 , 0.42 M NaCl, 0.2 mM EDTA, and 25% (v/v) glycerol, and then 0.1 M DTT and protease inhibitor cocktail were added. The mixture was placed on ice for 30 min. The nuclear fraction was prepared by centrifugation at 20,500 × g for 5 min at 4°C. The protein concentration was determined using a commercial kit (Bio-Rad Laboratories, Hercules, CA, USA).
Western blot analyses
For the determination of PPARα and SREBP-1, 10 μg of protein of each nuclear fraction was electrophoresed through 8% SDS-PAGE. Separated proteins were transferred to a nitrocellulose membrane, blocked with 5% (w/v) skim milk solution for 1 h, and then incubated with primary antibodies to PPARα, SREBP-1, and histone, respectively, overnight at 4°C. After the blots were washed, they were incubated with anti-rabbit or anti-mouse IgG horseradish peroxidase-conjugated secondary antibody for 1.5 h at room temperature. Each antigen-antibody complex was visualized using ECL Western Blotting Detection Reagents and detected by chemiluminescence with LAS-4000 (Fujifilm, Tokyo, Japan). Band densities were determined using ATTO Densitograph Software (ATTO Corporation, Tokyo, Japan) and quantified as the ratio to histone. These protein levels of groups are expressed relative to those of m/m mice (represented as 1).
PCR
Total RNA was isolated from hepatic tissue using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and quantified using NanoDrop (Thermo Scientific, Wilmington, DE, USA). The cDNAs were synthesized from 5 mg of RNA employing reverse transcriptase (Qiagen, Tokyo, Japan). For the realtime PCR, triplicate aliquots of serially diluted cDNA samples were used in a reaction mixture that contained 1 mM of each primer in a reaction volume of 50 mL employing the SYBR Green Real-time PCR kit (Qiagen) using a fluorometric thermal cycler (Mx3000P TM ; Stratagene, La Jolla, CA, USA). Reaction mixtures were incubated for an initial denaturation at 95°C for 15 min, followed by 45 cycles of 94°C for 15 s, 60°C for 30 s, and 72°C for 30 s. Primers used were as follows: acetyl-CoA carboxylase (ACC, sense: CCCAGCAGAATAAAGCTACTTTGG, antisense: TCCTTTTGTGCAACTAGGAACGT), FAS (sense: CCTGGATAGCATTCCGAACCT, antisense: AGCACATCTCGAAGGCTACACA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous control. The DC T method was employed for relative quantification. The DC T value for each sample was determined by calculating the difference between the C T value of the target gene and that of the GAPDH reference gene. The normalized target gene expression level in the sample was calculated using the formula 2 -DDCT as the fold change over the control.
Statistical analysis
Data are expressed as mean values with their standard errors. Statistical comparisons were performed by oneway ANOVA followed by Duncan's multiple-range test. Statistical analysis was conducted using SAS (release 9.2; SAS Institute, Cary, NC, USA) and p < 0.05 was considered signifi cant.
Results
Culture cell experiments
Cell viability
To test the cytotoxic effects, MTT assays were conducted after treatment with various concentrations of Kangen-karyu during the adipogenesis of 3T3-L1 cells. The results of the MTT assay showed that Kangen-karyu did not decrease the cell viability up to the concentration of 250 μg/mL, as shown in Figure 1 . Orlistat, which inhibits the absorption of neutral lipids and cholesterol by specifi cally inhibiting lipase (23) , at a concentration of 20 μM (10 μg/mL) did not affect the cell viability.
Lipid accumulation
As shown in Figure 2A , Kangen-karyu significantly inhibited the accumulation of lipid droplets at a concentration of 50 and 250 μg/mL. As the main components of fat droplets are lipids in the form of TG, the TG contents of cells were determined. As shown in Figure 2B , Kangen-karyu reduced TG accumulation. When the 3T3-L1 cells were treated with orlistat, TG accumulation was reduced by 36% at a concentration of 20 μM.
PPARγ and aP2 protein expressions
As shown in Figure 3 , the levels of PPARγ (A) and aP2 (B) were significantly inhibited by treatment with both 50 and 250 μg/mL Kangen-karyu. The effects of Kangenkaryu on PPARγ were more prominent than those of aP2.
PPARγ, SREBP-1c, and FAS mRNA expressions
The treatment with Kangen-karyu at 250 μg/mL led to a signifi cant inhibition of PPARγ, SREBP-1c, and FAS mRNA expressions, as shown in Figure 4 . In particular, the effect of PPARγ was marked and distinct from those of the other mRNA expressions.
Animal experiments
Body weight, food intake, and water intake
The db/db mice displayed typical phenotypes of obesity-induced diabetes with a marked increase in body weight gain, food intake, and water intake, as compared with m/m mice (normal control). The gain of body weight in db/db mice was non-significantly decreased by Kangen-karyu administration. The food and water intakes in db/db mice were significantly decreased by 100 mg/kg of Kangen-karyu treatment.
Hematological analyses
All serum constituents were elevated in vehicle-treated db/db mice compared with m/m mice. As shown in Table 2 , Kangen-karyu 200 mg/kg-administered db/ db mice groups showed decreased serum glucose and leptin, but no alteration of insulin. Furthermore, the administration of Kangen-karyu to db/db mice significantly improved TG, LDL/VLDL cholesterol, and NEFA compared with the db/db control group. Regarding hepatic function parameters, serum ALT and AST levels in vehicle db/db mice were elevated compared with those in m/m mice, while, in Kangenkaryu-administered db/db mice, these two parameters were slightly decreased.
Hepatic TG content
Compared with m/m mice, the liver weight of db/ db mice was significantly augmented, but the administration of Kangen-karyu led to a significant decrease in its weight. Concerning the hepatic content of TG, the db/db control group showed a marked increase compared with the m/m group. This TG content was significantly decreased by Kangen-karyu administration at a dose of 100 and 200 mg/kg body weight/day, as shown in Table 3 .
Hepatic PPARα and SREBP-1 protein expressions
As shown in Figure 5B , protein expression of hepatic SREBP-1 was markedly increased in the db/db control group compared with the m/m group. The administration of Kangen-karyu at 100 and 200 mg/ kg led to a significant down-regulation of SREBP-1 expression. While, in the case of hepatic PPARα, no signifi cant difference among the groups was observed ( Figure 5A ).
Hepatic mRNA expressions involved in TG metabolism
The effects of Kangen-karyu administration on the mRNA levels of genes involved in lipid metabolism in the hepatic tissue are presented in Figure 6 . Overexpressions of ACC and FAS mRNA were seen in hepatic tissue of the db/db vehicle group compared with m/m group. On the other hand, the administration of Kangen-karyu at a dose of 200 mg/kg body weight/day signifi cantly inhibited the expressions of ACC and FAS in db/db mice.
Discussion
D y s r e g u l a t i o n o f t h e p a t h w a y s i n v o l v e d i n adipogenesis, lipid metabolism, and energy homeostasis can lead to the development of obesity, hepatic steatosis, diabetes, and dyslipidemia. The transcription factors PPARγ and CCAAT/enhancer-binding protein-α (C/EBPα) play a crucial role during adipogenesis. In the later stages of terminal differentiation, proteins such as adipocyte-specific fatty acid-binding protein (aP2), adiponectin, and leptin are expressed. A fine balance between adipocyte hypertrophy and adipogenesis exists to prevent the formation of dysfunctional adipose tissue, since large cells are more likely to be insulin-resistant and, therefore, can infl uence adipose tissue metabolism.
Adipose tissue, as a metabolic and endocrine organ, plays critical roles in the regulation of energy balance, lipid metabolism, and insulin action. Obesity is a major public health problem involving increased risks of diabetes and cardiovascular disease in many countries. Adipocytes have been emerging as a potential pharmacological target for obesity, diabetes, and cardiovascular diseases (24) (25) (26) . Numerous studies have demonstrated that adipocyte differentiation and the amount of fat accumulation are associated with the occurrence and development of obesity. The findings of this study show that Kangen-karyu plays 
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The differentiation of preadipocytes into adipocytes is regulated by the coordinated expression of various transcription factors, and the induction of metabolic pathways related to lipid metabolism induces the expression of several adipocyte-specific genes like PPARγ, SREBP-1c, and FAS (27) . In addition, lipid homeostasis is regulated by a family of membranebound transcription factors called SREBPs (28) . SREBP-1 is a key transcription factor that nutritionally regulates the hepatic gene expression of lipogenic enzymes and TG deposition in the liver (29) . In the present study, Kangen-karyu significantly downregulated the mRNA levels of PPARγ, SREBP-1c, and FAS, and the protein levels of aP2 and PPARγ in mature adipocytes. These results suggest that Kangen-karyu inhibited adipocyte differentiation and adipogenesis by affecting the transcriptional factor cascade upstream of PPARγ, SREBP-1c, FAS, and aP2, possibly resulting in the inhibition of lipid accumulation by inhibiting adipogenesis.
As an experimental model of dyslipidemiaassociated type 2 diabetes mellitus, db/db mice are widely used and well-established (19, 30) . C57BLKS/ J db/db mice develop diabetes due to mutation of the mouse diabetes (db) gene that encodes a receptor for leptin. The lack of leptin-receptor signaling results in increased food intake in combination with a phenotype of reduced energy expenditure, reminiscent of the neuroendocrine starvation response (31) . Consequently, the homozygotes (db/db) after birth show unrepressed eating behavior, become obese, and, by 3-6 months after birth, develop severe insulin resistance associated with hyperinsulinemia, hyperglycemia, and hypertriglyceridemia. Therefore, in this study, we investigated whether Kangen-karyu ameliorates metabolic disorders including hyperlipidemia, using well-established db/db type 2 diabetic mice.
The effects of Kangen-karyu on serum lipid levels such as TG, total cholesterol, HDL cholesterol, LDL/VLDL cholesterol, and NEFA were examined. We found that db/db mice showed hyperlipidemia. However, the administration of Kangen-karyu reduced hyperlipidemia through lowering TG, LDL/VLDL cholesterol, and NEFA. Also, to investigate the effects of Kangen-karyu on hepatic damage induced by abnormal lipid synthesis, the lipid contents in the liver of db/db mice were also examined. The hepatic content of TG was signifi cantly decreased by the administration of Kangen-karyu. These results mean that Kangenkaryu may inhibit fat deposit or lipid output to blood with the regulation of lipid metabolism such as TG synthesis in type 2 diabetes.
Up-regulation of SREBP-1 was reported in leptinresistant mice, such as ob/ob mice and FVB db/db mice (32, 33) . In this study, the increase in hepatic SREBP-1 in db/db mice was down-regulated by the administration of Kangen-karyu. This was probably related to the inhibition of hepatic TG accumulations. Furthermore, PPARs, with three isoforms (α, δ, and γ), are also involved in the longterm regulation of lipid metabolism, and their activity is modulated by endogenous lipid-derived ligands. When PPARα is activated, it promotes fatty acid oxidation, ketone body synthesis, and glucose sparing (34) . In our study, hepatic PPARα was decreased in db/db mice; it was increased slightly, but not signifi cantly, by Kangenkaryu administration. However, we found that Kangenkaryu exhibits a significant effect on regulation of SREBP-1. These results suggest that Kangen-karyu has an ameliorating effect on dyslipidemia in type 2 diabetic mice through the regulation of impaired hepatic SREBPs.
It is well known that SREBP-1 primarily controls genes involved in fatty acid synthesis (29) . These include the genes for ACC and FAS in the fatty acid synthesis pathway (35) . Type 2 diabetes is associated with increased de novo lipogenesis, decreased plasma fatty acid oxidation, and increased fatty acid fl ux from peripheral tissues to the liver (36) . Therefore, we examined the effect of Kangen-karyu on regulating lipogenic enzyme genes such as ACC and FAS involved in fatty acid synthesis in the db/db mice liver using a real-time quantitative PCR technique. Our results strongly suggest that Kangen-karyu mediates the TGlowering action by reducing the expression of ACC and FAS, thereby inhibiting fatty acid synthesis in type 2 diabetic mice.
Another fi nding noted in this study was that Kangenkaryu treatment improved impaired liver function in type 2 diabetic mice. Elevated serum levels of ALT and AST usually indicate hepatocyte damage (37) . In db/db mice, serum ALT and AST were notably increased, but Kangen-karyu treatment showed a tendency to reduce these parameters, suggesting that Kangen-karyu might play an important role in improving liver function.
Thiazolidinediones and fibrate drugs are the most commonly used medications for type 2 diabetes mellitus, hyperlipidemia, and insulin resistance. They bind to and activate PPARs, which results in the upregulation of several genes involved in glucose and lipid metabolism (38) . PPARs are currently viewed as potential therapeutic targets for the treatment of diabetes and dyslipidemia. PPARγ, predominantly expressed in adipose tissue and macrophages (39) , affects genes involved in lipid synthesis and storage, and glucose homeostasis. PPARγ agonists, such as thiazolidinediones, control lipid metabolism and insulin sensitivity. However, several concerns such as body weight gain associated with an excess increase of fat mass arise in type 2 diabetes mellitus patients (40) . Accumulating evidence indicates that the activation of PPARα stimulates lipid consumption by enhancing the expression of fatty acid oxidation genes, resulting in the amelioration of hyperlipidemia (41) . PPARα agonists, such as fenofi brate used for the treatment of hyperlipidemia and reducing cardiovascular disease, have a potent effect on reducing plasma TG (42) . Because of these distinct metabolic effects of PPARα and PPARγ agonists on insulin sensitivity and lipid metabolism, new drug development has focused on dual PPARs which possess PPARγ as well as PPARα activity. In this study, we initially assessed the protective effects of Kangen-karyu against type 2 diabetes by investigating specifi c markers in the serum and hepatic tissue of db/db mice, thereby highlighting Kangen-karyu as a promising anti-lipotoxic agent for type 2 diabetes.
